APA (7th ed.) Citation

Vogel, A., Boeck, S., Waidmann, O., Bitzer, M., Wenzel, P., Belle, S., . . . Saborowski, A. (2022). 52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC). Annals of Oncology, 33, S563. https://doi.org/10.1016/j.annonc.2022.07.080

Chicago Style (17th ed.) Citation

Vogel, A., et al. "52MO A Randomized Phase II Trial of Durvalumab and TremelIMUmab with Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients with CHolangio- and GallbladdEr Carcinoma (IMMUCHEC)." Annals of Oncology 33 (2022): S563. https://doi.org/10.1016/j.annonc.2022.07.080.

MLA (9th ed.) Citation

Vogel, A., et al. "52MO A Randomized Phase II Trial of Durvalumab and TremelIMUmab with Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients with CHolangio- and GallbladdEr Carcinoma (IMMUCHEC)." Annals of Oncology, vol. 33, 2022, p. S563, https://doi.org/10.1016/j.annonc.2022.07.080.